Improved residual fat malabsorption and growth in children with cystic fibrosis treated with a novel oral structured lipid supplement: A randomized controlled trial

BACKGROUND: In the primary analysis of a 12-month double-blind randomized active placebo-controlled trial, treatment of children with cystic fibrosis (CF) and pancreatic insufficiency (PI) with a readily absorbable structured lipid (Encala™, Envara Health, Wayne, PA) was safe, well-tolerated and imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Stallings, Virginia A., Tindall, Alyssa M., Mascarenhas, Maria R., Maqbool, Asim, Schall, Joan I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209323/
https://www.ncbi.nlm.nih.gov/pubmed/32384122
http://dx.doi.org/10.1371/journal.pone.0232685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209323/
https://www.ncbi.nlm.nih.gov/pubmed/32384122
http://dx.doi.org/10.1371/journal.pone.0232685

Ejemplares similares